Research programme: inflammation therapeutics - Centocor/Shanghai Genomics
Latest Information Update: 16 Jul 2016
At a glance
- Originator Centocor; Shanghai Genomics
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Cancer; Inflammation
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Inflammation in China
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in China
- 25 Jul 2006 Preclinical trials in Inflammation in China (unspecified route)